Germany confirmed not to sell its COVID-19 vaccine research to the United States

The German Foreign Ministry said it was studying the vaccine for COVID-19 “not for sale” after it was announced that President Donald Trump proposed buying the copyright of the vaccine from the biotechnology company CureVac (Germany).

A race for monopoly between Germany and the US took place when scientists tried to develop a new strain of coronavirus vaccine (SARS-CoV-2) that causes COVID-19, which has killed over 6,500 people worldwide.

The statement came after Die Welt quoted German government sources as revealing that President Trump had offered “$ 1 billion” to secure vaccine research by German biotech company CureVac exclusively for the US.

Responding to this information, German Economy Minister Peter Altmaier bluntly asserted: “Germany is not for sale”. At the same time, Interior Minister Horst Seehofer said the government would hold a meeting to discuss the issue of monopoly in vaccine research.

In a statement, CureVac stated not to comment on its speculations and dismissed allegations of the company’s offer of acquisition or technology. “Currently international cooperation is important, not for the sake of an individual country,” said Erwin Rueddel, a conservative legislator on the health committee of the German parliament.

Meanwhile, AFP quoted a US official as saying that the German media went too far. US officials also denied that Washington was seeking to “keep the COVID-19 vaccine for the United States only.” “We will continue to discuss with any company that claims to be able to successfully,” he said. All effective solutions will be shared with the world”.

Founded in 2000, CureVac has offices in Frankfurt (Germany) and Boston (USA). CureVac advertises as a company specializing in the development of antibody-based cancer therapy, rare diseases and preventive vaccines.

CureVac CEO Daniel Menichella was invited to meet with President Trump and Vice President Mike Pence at the White House in Washington D.C. on 2 March.